IJCM  Vol.10 No.10 , October 2019
Pathogenic Mycoplasma Infections in Chronic Illnesses: General Considerations in Selecting Conventional and Integrative Treatments
Abstract: The presence of pathogenic mycoplasmas in various chronic illnesses and their successful suppression using conventional and integrative medicine approaches are reviewed. Evidence gathered over the last three decades has demonstrated the presence of pathogenic mycoplasma species in the blood, body fluids and tissues from patients with a variety of chronic clinical conditions: atypical pneumonia, asthma and other respiratory conditions; oral cavity infections; urogenital conditions; neurodegenerative and neurobehavioral diseases; autoimmune diseases; immunosuppressive diseases; inflammatory diseases; and illnesses and syndromes of unknown origin, such as fatiguing illnesses. Only recently have these small intracellular bacteria received attention as possible causative agents, cofactors or opportunistic infections or co-infections in these and other conditions. Their clinical management is often inadequate, primarily because of missed diagnosis, under- and inadequate treatment and the presence of persister or dormant microorganisms due to biofilm, resistence and other mechanisms. Pathogenic Mycoplasma species infections have been suppressed slowly by anti-microbial and integrative treatments, resulting in gradual reductions in morbidity, but not in every patient. Even if mycoplasmas are not a cause or an initial trigger for many chronic illnesses, they appear to play important roles in the inception, progression, morbidity and relapse of chronic illnesses in rather large patient subsets. Ignoring such infections can result in failure to achieve eventual patient recovery, even with application of potentially curative treatments.
Cite this paper: Nicolson, G. (2019) Pathogenic Mycoplasma Infections in Chronic Illnesses: General Considerations in Selecting Conventional and Integrative Treatments. International Journal of Clinical Medicine, 10, 477-522. doi: 10.4236/ijcm.2019.1010041.

[1]   Razin, S, Yogev, D. and Naot, Y. (1998) Molecular Biology and Pathogenicity of Mycoplasmas. Microbiology and Molecular Biology Reviews, 62, 1094-1156.

[2]   Narita, M. (2016) Classification of Extrapulmonary Manifestations Due to Mycoplasma pnaumoniae Infection on the Basis of Possible Pathogenesis. Frontiers in Microbiology, 7, Article 23.

[3]   Taylor-Robinson, D. and Jensen, J.S. (2011) Mycoplasma genitalium: From Chrysalis to Multicolored Butterfly. Clinical Microbiology Reviews, 24, 498-514.

[4]   Atkinson, T.P. (2018) Mollicutes: Mycoplasma pneumoniae. In: Ragab, G., Atkinson, T., Prescott, S. and Matthew, L., Eds., The Microbiome in Rheumatic Diseases and Infection, Springer International Publishing, Berlin, 103-111.

[5]   Baseman, J.B. and Tully, J.G. (1997) Mycoplasmas: Sophisticated, Reemerging, and Burdened by Their Notoriety. Emerging Infectious Diseases, 3, 21-32.

[6]   Nicolson, G.L., Nasralla, M.Y., Haier, J., Erwin, R., Nicolson, N.L. and Ngwenya, R. (1999) Mycoplasmal Infections in Chronic Illnesses: Fibromyalgia and Chronic Fatigue Syndromes, Gulf War Illness, HIV-AIDS and Rheumatoid Arthritis. Medical Sentinel, 4, 172-176.

[7]   Nicolson, G.L., Nasralla, M.Y. and Nicolson, N.L. (1999) The Pathogenesis and Treatment of Mycoplasmal Infections. Antimicrobial and Infectious Disease Newsletter, 17, 81-87.

[8]   Agnas, B. (1997) Sexual Transmitted Diseases (Mycoplasma homonis, Ureaplasma urealyticum and Chlamydia trachomatis) among Young Females. Orvosi Hetilap (Hungarian Medical Journal), 138, 799-803.

[9]   Svenstrup, H.F., Fedder, J., Kristoffersen, S.E., Trolle, B., Birkelund, S. and Christiansen, G. (2008) Mycoplasma genitalium, Chlamydia trachomatis and Tubal Factor Infertility—A Prospective Study. Fertility and Sterility, 90, 513-520.

[10]   Murtha, A.P. and Edwards, J.M. (2014) The Role of Mycoplasma and Ureaplasma in Adverse Pregnancy Outcomes. Obstetrics and Gynecology Clinics of North America, 41, 615-627.

[11]   Bitnun, A. and Richardson, S.E. (2010) Mycoplasma pneumoniae: Innocent Bystander or a True Cause of Central Nervous System Disease? Current Infectious Disease Report, 12, 282-290.

[12]   Weidenfeld, J., Wohlman, A. and Gallily, R. (1995) Mycoplasma fermentans Activates the Hypothalamo-Pituitary Adrenal Axis in the Rat. NeuroReport, 6, 910-912.

[13]   Wohlman, A., Gallily, R., Yirmiya, R. and Weidenfeld, J. (1997) Characterization of the Effect of Mycoplasma fermentans on the Hypothalamo-Pituitary-Adrenal Axis. Neuroendocrinology, 66, 221-228.

[14]   Fadiel, A., Eichenbaum, K.D., El Semary, N. and Epperson, B. (2007) Mycoplasma Genomics: Tailoring the Genome for Minimal Life Requirements through Reductive Evolution. Frontiers in Bioscience, 12, 2020-2028.

[15]   Razin, S. (1985) Molecular Biology and Genetics of Mycoplasmas (Mollicutes). Microbiological Reviews, 49, 419-455.

[16]   Razin, S. (1997) Comparative Genomics of Mycoplasmas. Weiner Klinischer Wochenschrift, 109, 551-556.

[17]   Glass, J.I., Assad-Garcia, N., Alperovich, N., Yooseph, S., Lewis, M.R., Maruf, M., Hutchison, C.A., Smith, H.O. and Venter, J.C. (2006) Essential Genes of a Minimal Bacterium. Proceedings of the National Academy of Sciences of the United States of America, 103, 425-430.

[18]   Reddy, S.P., Rasmussen, W.G. and Baseman, J.B. (1996) Isolation and Characterization of Transposon Tn4001-Generated, Cytadherence-Deficient Transformants of Mycoplasma pneumoniae and Mycoplasma genitalium. FEMS Immunology and Medical Microbiology, 15, 199-211.

[19]   Baseman, J.B., Reddy, S.P. and Dallo, S.F. (1996) Interplay between Mycoplasma Surface Proteins, Airway Cells, and the Protean Manifestations of Mycoplasma-Mediated Human Infections. American Journal of Respiratory and Critical Care Medicine, 154, S137-S144.

[20]   Schaeverbeke, T., Vernhes, J.P., Lequen, L., Bannwarth, B., Bebear, C. and Dehais, J. (1997) Mycoplasmas and Arthritides. Reviews in Rheumatology English Education, 64, 120-128.

[21]   Rottem, S. (2003) Interaction of Mycoplasmas with Host Cells. Physiological Reviews, 83, 417-432.

[22]   Klement, M.L., Öjemyr, L., Tagscherer, K.E., Widmalm, G. and Wieslander, A. (2007) A Processive Lipid Glycosyltransferase in the Small Human Pathogen Mycoplasma pneumoniae: Involvement in Host Immune Response. Molecular Microbiology, 65, 1444-1457.

[23]   Zhang, Q. and Wise, K.S. (1996) Molecular Basis of Size and Antigenic Variation of a Mycoplasma hominis Adhesin Encoded by Divergent vaa Genes. Infection and Immunity, 64, 2737-2744.

[24]   McGowin, C.L. and Totten, P.A. (2017) The Unique Microbiology and Molecular Pathogenesis of Mycoplasma genitalium. Journal of Infectious Diseases, 216, S382-S388.

[25]   Burgos, R., Pich, O.Q., Ferrer-Navorro, M., Baseman, J.B., Querol, E. and Pinol, J. (2006) Mycoplasma genitalium P140 and P110 Cytadhesions Are Reciprocally Stabilized and Required for Cell Adhesion and Terminal-Organelle Development. Journal of Bacteriology, 188, 8627-8637.

[26]   Svenstrup, H.F., Jensen, J.S., Gevaert, K., Birkelund, S. and Christiansen, G. (2006) Identification and Characterization of Immunogenic Proteins of Mycoplasma genitalium. Clinical and Vaccine Immunology, 13, 913-922.

[27]   Christodoulides, A., Gupta, N., Yacoubian, V., Maithel, N., Parker, J. and Kelesides, T. (2018) The Role of Lipoproteins in Mycoplasma-Mediated Immunomodulation. Frontiers in Microbiology, 9, Article 1682.

[28]   Zhang, Y., Mei, S., Zhou, Y., Huang, M., Dong, G. and Chen, Z. (2016) Cytokines as the Good Predictors of Refractory Mycoplasma pneumoniae Pneumonia in School-Aged Children. Scientific Reports, 6, Article No. 37037.

[29]   Mühlradt, P.F., Kiess, M., Meyer, H., Süssmuth, R. and Jung, G. (1997) Insolation, Structure Elucidation, and Synthesis of a Macrophage Stimulatory Lipoprotein from Mycoplasma fermentans Acting at Picomolar Concentration. Journal of Experimental Medicine, 185, 1951-1958.

[30]   Mühlradt, P.F., Meyer, H. and Jansen, R. (1996) Identification of S-(2,3-Dihydrox-ypropyl)Cystein in a Macrophage-Activating Lipopeptide from Mycoplasma fermentans. Biochemistry, 35, 7781-7786.

[31]   Frisch, M., Gradehandt, G. and Muhlradt, P.F. (1996) Mycoplasma fermentans-Derived Lipid Inhibits Class II Major Histocompatibility Complex Expression without Mediation by Interleukin-6, Interleukin-10, Tumor Necrosis Factor, Transforming Growth Factor-Beta, Type I Interferon, Prostaglandins or Nitric Oxide. European Journal of Immunology, 26, 1050-1057.

[32]   Sasaki, Y., Blanchard, A., Watson, H.L., Garcia, S., Dulioust, A., Montagnier, L. and Gougeon, M.L. (1995) In Vitro Influence of Mycoplasma penetrans on Activation of Peripheral T Lymphocytes from Healthy Donors or Human Immunodeficiency Virus-Infected Individuals. Infection and Immunity, 63, 4277-4283.

[33]   Kaufmann, A., Mühlradt, P.F., Gemsa, D. and Sprenger, H. (1999) Induction of Cytokines and Chemokines in Human Monocytes by Mycoplasma fermentans-Derived Lipoprotein MALP-2. Infection and Immunity, 67, 6303-6308.

[34]   Brenner, C., Wroblewski, H., Henaff, M.L., Montagnier, L. and Blanchard, A. (1997) Spiralin, a Mycoplasmal Membrane Protein, Induces T-Cell-Independent B-Cell Blastogenesis and Secretion of Proinflammatory Cytokines. Infection and Immunity, 65, 4322-4329.

[35]   He, J., Liu, M., Ye, Z., Tan, T., Liu, X., You, X., Zeng, Y. and Wu, Y. (2016) Insights into the Pathogenesis of Mycoplasma penumoniae. Molecular Medicine Reports, 14, 4030-4036.

[36]   Bendjennat, M., Blanchard, A., Loutfi, M., Montagnier, L. and Bahraoui, E. (1999) Role of Mycoplasma penetrans Endonuclease P40 as a Potential Pathogenic Determinant. Infection and Immunity, 67, 4456-4462.

[37]   Minion, F.C., Jarvill-Taylor, K.J., Billings, D.E. and Tigges, E. (1993) Membrane-Associated Nuclease Activities in Mycoplasmas. Journal of Bacteriology, 175, 7842-7847.

[38]   Saitoh, S., Wada, T., Narita, M., Kohsaka, S., Mizukami, S., Togashi, T. and Kajii, N. (1993) Mycoplasma pneumoniae Infection May Cause Striatal Lesions Leading to Acute Neurologic Dysfunction. Neurology, 43, 2150-2151.

[39]   Rawadi, G., Roman-Roman, S., Castedo, M., Dutilleul, V., Susin, S., Marchetti, P., Geuskens, M. and Kroemer, G. (1996) Effects of Mycoplasma fermentans on the Myelomonocytic Linage. Different Molecular Endities with Cytokine-Inducing and Cytocidal Potential. Journal of Immunology, 156, 670-678.

[40]   Waites, K.B., Xiao, L., Liu, Y., Balish, M.F. and Atkinson, T.P. (2017) Mycoplasma pneumonia from the Respiratory Tract and beyond. Clinical Microbiology Reviews, 30, 747-809.

[41]   Komada, Y., Zhang, X.L., Zhou, Y.W., Ido, M. and Azuma, E. (1997) Apoptotic Cell Death of Human Lymphoblastoid Cells Induced by Arginine Deaminase. International Journal of Hematology, 65, 129-141.

[42]   Molinos, L., Fernandez, R., Dominguez, M.J., Riesgo, C., Escudero, C. and Martinez, J. (1997) Adenosine Deaminase Activity in the Aetiological Diagnosis of Community-Acquired Pneumonia. Scandinavian Journal of Infectious Disease, 29, 287-290.

[43]   Becker, A., Kannan, T.R., Taylor, A.B., Pakhornova, O.N., Zhang, Y., Somarajan, S.R., Galaleldeen, A., Holloway, S.P., Baseman, J.B. and Hart, P.J. (2015) Structure of CARDS Toxin, a Unique ADP-Ribosylating and Vacuolating Cytotoxin from Mycoplasma pneumoniae. Proceedings of the National Academy of Sciences of the United States of America, 112, 5165-5170.

[44]   Muir, M.T., Cohn, S.M., Louden, C., Kannan, T.R. and Baseman, J.B. (2011) Novel Toxin Assays Implicate Mycoplasma pneumoniae in Prolonged Ventilator Course and Hypoxemia. Chest, 139, 305-310.

[45]   Nicolson, G.L. (2008) Chronic Infections in Neurodegenerative and Neurobehavioral Diseases. Laboratory Medicine, 39, 291-299.

[46]   Nicolson, G.L. and Haier, J. (2009) Role of Chronic Bacterial and Viral Infections in Neurodegenerative, Neurobehavioral, Psychiatric, Autoimmune and Fatiguing Illnesses: Part 1. British Journal of Medical Practitioners, 2, 20-28.

[47]   Nicolson, G.L. and Haier, J. (2010) Role of Chronic Bacterial and Viral Infections in Neurodegenerative, Neurobehavioral, Psychiatric, Autoimmune and Fatiguing Illnesses: Part 2. British Journal of Medical Practitioners, 3, 301-311.

[48]   Nicolson, G.L. and Nicolson, N.L. (1996) Diagnosis and Treatment of Mycoplasmal Infections in Persian Gulf War Illness-CFIDS Patients. International Journal of Occupational Medicine, Immunology and Toxicology, 5, 69-78.

[49]   Lin, L.-J., Chang, F.-C., Chi, H., Jim, W.-T., Huang, D.T., Kung, Y.-H., Huang, C.-Y., Chiu, N.-C. and Chang, L. (2019) The Diagnostic Value of Serological Studies in Pediatric Patients with Acute Mycoplasma pneumonia Infection. Journal of Microbiology, Immunology and Infection, in press.

[50]   Sauter, P.M., van Rossum, A.M.C. and Vink, C. (2014) Mycoplasma pneumoniae in Children: Carriage, Pathogenesis and Antibiotic Resistance. Current Opinion in Infectious Diseases, 27, 220-227.

[51]   Jacobs, E., Ehrhardt, I. and Dumke, R. (2015) New Insights in the Outbreak Pattern of Mycoplasma pneumoniae. International Journal of Medical Microbiology, 305, 705-708.

[52]   Cimolai, N., Wensley, D., Seear, M. and Thomas, E.T. (1995) Mycoplasma pneumoniae as a Cofactor in Severe Respiratory Infections. Clinical Infectious Diseases, 21, 1182-1185.

[53]   Gray, G.C., Duffy, L.B., Paver, R.J., Putnam, S.D., Reynolds, R.J. and Cassell, G.H. (1997) Mycoplasma pneumoniae: A Frequent Cause of Pneumonia among U.S. Marines in Southern California. Military Medicine, 162, 524-526.

[54]   Mishra, R., Cano, E., Venkatram, S. and Diaz-Fuentes, G. (2017) An Interesting Case of Mycoplasma Pneumonia Associated Multisystem Involvement and Diffuse Alveolar Hemorrhage. Respiratory Medicine Case Reports, 21, 78-81.

[55]   Jackson, D.J., Gern, J.E. and Lemanske Jr., R.F. (2016) The Contributions of Allergic Sensitization and Respiratory Pathogens to Asthma Inception. Clinical Reviews in Allergy and Immunology, 137, 659-665.

[56]   Holt, R.D., Wilson, M. and Musa, S. (1995) Mycoplasmas in Plaque and Saliva of Children and Their Relationship to Gingivitis. Journal of Periodontology, 66, 97-101.

[57]   Kwek, H.S., Wilson, M. and Newman, H.N. (1990) Mycoplasma in Relation to Gingivitis and Periodontitis. Journal of Clinical Periodontology, 17, 119-122.

[58]   Borak, J. and Lefkowitz, R.Y. (2016) Bronchial Hyperresponsiveness. Occupational Medicine, 66, 95-105.

[59]   Parrott, G.L., Kinjo, T. and Fujita, J. (2016) A Compendium for Mycoplasma pneumoniae. Frontiers in Microbiology, 7, Article 513.

[60]   Seggev, J.S., Sedmak, G.V. and Kurup, V. (1996) Isotype-Specific Antibody Responses to Acute Mycoplasma pneumoniae Infection. Annals of Allergy, Asthma and Immunology, 77, 67-73.

[61]   Combaz-Söhnchen, N. and Kuhn, A. (2017) A Systematic Review of Mycoplasma and Ureaplasma in Urogynaecology. Geburtschilfe und Frauenheilkunde, 77, 1299-1303.

[62]   Mardh, P.A., Elshibly, S., Kallings, I. and Hellberg, D. (1997) Vaginal Flora Changes Associated with Mycoplasma hominis. American Journal of Obstretrics and Gynecology, 176, 173-178.

[63]   Al-Farraj, D.A. and Moubayed, N.M. (2019) The Association between Sociodemographic, Hormonal, Tubo-Ovanian Factors and Bacterial Count in Chlamydia and Mycoplasma Infections with Infertility. Saudi Journal of Biological Sciences, 26, 20-23.

[64]   Waites, K.B., Katz, B. and Schelonka, R.L. (2005) Mycoplasmas and Ureaplasmas as Neonatal Pathogens. Clinical Microbiology Reviews, 18, 757-789.

[65]   Schuppe, H.C., Pilatz, A., Hossain, H., Diemer, T., Wagenlehner, F. and Weidner, W. (2017) Urogenital Infection as a Risk Factor for Male Infertility. Deutsches Ärzteblatt International, 114, 339-346.

[66]   Cassell, G.H., Waites, K.B., Watson, H.L., Crouse, D.T. and Harasawa, R. (1993) Ureaplasma urealyticum Intraurerine Infection: Role in Prematurity and Diseases in Newborns. Clinical Microbiology Reviews, 6, 69-87.

[67]   Lemaitre, M., Henin, Y., Destouesse, F., Ferrieux, C., Montagnier, A. and Blanchard, A. (1992) Role of Mycoplasmas in the Cytopathic Effect Induced by Human Immunodeficiency Virus Type 1 in Infected Cell Lines. Infection and Immunity, 60, 742-748.

[68]   Ainsworth, J.G., Katseni, V., Hourshid, S., Ball, S., Cattell, V. and Taylor-Robinson, D. (1994) Mycoplasma fermentans and HIV-Associated Nephropathy. Journal of Infection, 29, 323-326.

[69]   Blanchard, A. (1997) Mycoplasmas and HIV Infection, a Possible Interaction through Immune Activation. Wien Klinische Wochenschrift, 109, 590-593.

[70]   Montagnier, L. and Blanchard, A. (1993) Mycoplasmas as Cofactors in Infection Due to the Immunodeficiency Virus. Clinical Infectious Disease, 17, S309-S315.

[71]   Li, J.-L., Matsuda, K., Takagi, M. and Yamamoto, N. (1997) Detection of Antibodies against Phosphocholine-Containing Aminoglycoglycerolipid Specific to Mycoplasma fermentans in HIV-1 Infected Individuals. Journal of Immunological Methods, 208, 103-113.

[72]   Kocacic, R., Launay, V., Tuppin, P., Lafeuillade, A., Feuillie, V., Montagnier, L. and Grau, O. (1996) Search for the Presence of Six Mycoplasma Species in Peripheral Blood Mononuclear Cells of Subjects Seropositive and Seronegative for Human Immunodeficiency Virus. Journal of Clinical Microbiology, 34, 1808-1810.

[73]   Sloot, N., Hollandt, H., Gatermann, S. and Dalhoff, K. (1996) Detection of Mycoplasma sp. in Bronchoalveolar Lavage of AIDS Patients with Pulmonary Infiltrates. Zentralblatt für Bakeriologie, 284, 75-79.

[74]   Bisset, L.R. (1994) Molecular Mimicry in the Pathogenesis of AIDS: The HIV/ MHC/Mycoplasma Triangle. Medical Hypothesis, 43, 388-396.

[75]   Jefferies, W.M. (1998) The Etiology of Rheumatoid Arthritis. Medical Hypotheses, 51, 111-114.

[76]   Ford, D. (1991) The Microbial Causes of Rheumatoid Arthritis. Journal of Rheumatology, 18, 1441-1442.

[77]   Rivera, A., Yáñez, A., León-Tello, G., Gil, C., Barba, E. and Cedillo, L. (2002) Experimental Arthritis Induced by a Clinical Mycoplasma fermentans Isolate. BMC Musculoskeletal Disorders, 3, Article No. 15.

[78]   Schaeverbeke, T., Renaudin, H., Clerc, M., Lequen, L., Vernhes, J.P., De Barbeyrac, B., Bannwarth, B., Bébéar, C. and Dehais, J. (1997) Systemic Detection of Mycoplasmas by Culture and Polymerase Chain Reaction (PCR) Procedures in 209 Synovial Fluid Samples. British Journal of Rheumatology, 36, 310-314.

[79]   Haier, J., Nasralla, M., Franco, A.R. and Nicolson, G.L. (1999) Detection of Mycoplasmal Infections in Blood of Patients with Rheumatoid Arthritis. Rheumatology, 38, 504-509.

[80]   Furr, P.M., Taylor-Robinson, D. and Webster, A.D. (1994) Mycoplasmas and Ureaplasmas in Patients with Hypogammaglobulinaemia and Their Role in Arthritis: Microbiological Observations over Twenty Years. Annuals of Rheumatic Diseases, 53, 183-187.

[81]   Cole, B.C. and Griffith, M.M. (1993) Triggering and Exacerbation of Autoimmune Arthritis by the Mycoplasma arthritidis Superantigen MAM. Arthritis and Rheumatism, 36, 994-1002.

[82]   Kirchhoff, H., Binder, A., Runge, M., Meier, B., Jacobs, R. and Busche, K. (1989) Pathogenic Mechanisms in the Mycoplasma arthritidis Polyarthritis of Rats. Rheumatology International, 9, 193-196.

[83]   Narita, M. (2010) Pathogenesis of Extrapulmonary Manifestations of Mycoplasma pneumoniae Infection with Special Reference to Pneumonia. Journal of Infection and Chemotherapy, 16, 162-169.

[84]   Feizi, T. and Loveless, R.W. (1996) Carbohydrate Recognition by Mycoplasma pneumoniae and Pathologic Consequences. American Journal of Respiratory and Critical Care Medicine, 154, S133-S136.

[85]   Kaneoka, H. and Naito, S. (1997) Superantigens and Autoimmune Diseases. Nippon Rinsho. Japanese Journal of Clinical Medicine, 55, 1363-1369.

[86]   Mattson, M.P. (2004) Infectious Agents and Age-Related Neurodegenerative Disorders. Ageing Research Reviews, 3, 105-120.

[87]   Zasler, N.D., Martelli, M.F. and Jacobs, H.E. (2013) Neurobehavioral Disorders. Handbook of Clinical Neurology, 110, 377-388.

[88]   Walling, A.D. (1999) Amyotrophic Lateral Sclerosis: Lou Gehrig’s Disease. American Family Physician, 59, 1489-1496.

[89]   Nicolson, G.L., Nasralla, M., Haier, J. and Promfret, J. (2002) High Frequency of Systemic Mycoplasmal Infections in Gulf War Veterans and Civilians with Amyotrophic Lateral Sclerosis (ALS). Journal of Clinical Neurosciences, 9, 525-529.

[90]   Gil, C., González, A.A.S., León, I.S., Rivera, A., Olea, R.S. and Cedillo, L. (2014) Detection of Mycoplasmas in Patients with Amyotrophic Lateral Sclerosis. Advances in Microbiology, 4, 712-719.

[91]   Libbey, J.E., Cusick, M.F. and Fujinami, R.S. (2013) Role of Pathogens in Multiple Sclerosis. International Review of Immunology, 33, 266-283.

[92]   Bahar, M., Ashtari, F., Aghaei, M., Akbari, M., Salari, M. and Ghalamkari, S. (2012) Mycoplasma pneumoniae Seropositvity in Iranian Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized Case-Control Study. Journal of Pakistan Medical Association, 62, S6-S8.

[93]   Sriram, S., Mitchell, W. and Stratton, C. (1998) Multiple Sclerosis Associated with Chlamydia pneumoniae Infection of the CNS. Neurology, 50, 571-572.

[94]   Tselis, A. (2011) Evidence for Viral Etiology of Multiple Sclerosis. Seminars in Neurology, 31, 307-316.

[95]   Nicolson, G.L., Gan, R., Nicolson, N.L. and Haier, J. (2007) Evidence for Mycoplasma spp., Chlamydia pneumoniae, and Human Herpes Virus-6 in the Blood of Patients with Autistic Spectrum Disorders. Journal of Neuroscience Research, 85, 1143-1148.

[96]   Bransfield, R.C., Wulfman, J.S., Harvey, W.T. and Usman, A.I. (2008) The Association between Tick-Borne Infections, Lyme Borreliosis and Autism Spectrum Disorders. Medical Hypotheses, 70, 967-974.

[97]   Kuhn, M., Grave, S., Bransfield, R. and Harris, S. (2012) Long Term Antibiotic Therapy May Be an Effective Treatment for Children Co-Morbid with Lyme Disease and Autism Spectrum Disorder. Medical Hypotheses, 78, 606-615.

[98]   Fukuda, K., Strauss, S.E., Hickie, I., Sharpe, M.C., Dobbins, J.G. and Komaroff, A. (1994) The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study. Annals of Internal Medicine, 121, 953-959.

[99]   Carruthers, B.M., Jain, A.K., De Meirleir, K.L., Peterson, D.L., Klimas, N.G. and Lerner, A.M. (2003) Malgic Encephalomyelitis/Chronic Fatigue Syndrome. Clinical Working Case Definition, Diagnostic and Treatment Protocols. Journal of Chronic Fatigue Syndrome, 11, 7-115.

[100]   Nicolson, G.L., Nasralla, M., De Meirleir, K., Gan, R. and Haier, J. (2003) Evidence for Bacterial (Mycoplasma, Chlamydia) and Viral (HHV-6) Co-Infections in Chronic Fatigue Syndrome Patients. Journal of Chronic Fatigue Syndrome, 11, 7-19.

[101]   Nasralla, M., Haier, J. and Nicolson, G.L. (1999) Multiple Mycoplasmal Infections Detected in Blood of Patients with Chronic Fatigue Syndrome and/or Fibromyalgia. European Journal of Microbiology and Infectious Diseases, 18, 859-865.

[102]   Nijs, J., Nicolson, G.L., De Becker, P., Coomans, D. and De Meirleir, K. (2006) High Prevalence of Mycoplasma Infections among European Chronic Fatigue Syndrome Patients. Examination of Found Mycoplasma Species in Blood of Chronic Fatigue Syndrome Patients. FEMS Immunology and Medical Microbiology, 34, 209-214.

[103]   Nicolson, G.L., Gan, R. and Haier, J. (2003) Multiple Co-Infections (Mycoplasma, Chlamydia, Human Herpes Virus-6) in Blood of Chronic Fatigue Syndrome Patients: Association with Signs and Symptoms. Acta Pathologica Microbiologica Immunologica Scandanavia (APMIS), 111, 557-566.

[104]   Breeding, P.C., Russell, N.C. and Nicolson, G.L. (2012) Integrative Model of Chronically Activated Immune-Hormonal Pathways Important in the Generation of Fibromyalgia. British Journal of Medical Practitioners, 5, a524.

[105]   Nicolson, G.L., Nicolson, N.L., Berns, P., Nasralla, M.Y., Haier, J. and Nass, M. (2003) Gulf War Illnesses: Chemical, Biological and Radiological Exposures Resulting in Chronic Fatiguing Illnesses Can Be Identified and Treated. Journal of Chronic Fatigue Syndrome, 11, 135-154.

[106]   Janulewicz, P., Krengel, M., Quinn, E., Heeren, T., Toomey, R., Killiany, R., Zundel, C., Ajama, J., O’Callaghan, J., Steele, L., Klimas, N. and Sullivan, K. (2018) The Multiple Hit Hypothesis for Gulf War Illness: Self-Reported Chemical/Biological Weapons Exposure and Mild Traumatic Brain Injury. Brain Sciences, 8, Article 198.

[107]   Bach, J.F. (2005) Infections and Autoimmune Diseases. Journal of Autoimmunity, 25, 74-80.

[108]   Gorthi, S.P., Kapoor, L., Chaudhry, R., Sharma, N., Perez-Perez, G.I., Panigrahi, P. and Behari, M. (2006) Guillain-Barré Syndrome: Association with Campylobacter jujuniand, Mycoplasma pneumoniae Infections in India. National Medicine Journal India, 19, 137-139.

[109]   Shulman, S.T. and Stanford, T. (2009) Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococci (PANDAS): Update. Current Opinion in Pediatrics, 21, 127-130.

[110]   Müller, N., Riedel, M., Blendinger, C., Oberle, K., Jacobs, E. and Abele-Horn, M. (2004) Mycoplasma pneumoniae Infection and Tourette’s Syndrome. Psychiatry Research, 129, 119-125.

[111]   Krause, D.L. and Müller, N. (2012) The Relationship between Tourette’s Syndrome and Infections. Open Neurology Journal, 6, 124-128.

[112]   Ainsworth, J.G.E., Esterbrook, P.J., Clarke, J., Gilroy, C.B. and Taylor-Robinson, D. (2001) An Association of Disseminated Mycoplasma fermentans in HIV-1 Positive Patients with Non-Hodgkin’s Lymphoma. International Journal of STD and AIDS, 12, 499-504.

[113]   Henrich, B., Rumming, M., Sczyrba, A., Velleuer, E., Dietrich, R., Gerlach, W., Gombert, M., Rahn, S., Stoye, J., Borkhardt, A. and Fischer U. (2014) Mycoplasma salivarium as a Dominant Colonizer of Fanconi Anaemia Associated Oral Carcinoma. PLoS ONE, 9, e92297.

[114]   Barykova, Y.A., Logunov, D.Y., Shmarov, M.M., Vinarov, A.Z., Fiev, D.N., Vinarova, N.A., Rakovskaya, I.V., et al. (2011) Association of Mycoplasma hominis Infection with Prostate Cancer. Oncotargets, 2, 289-297.

[115]   Jiang, S., Zhang, S., Langenfeld, J., Lo, S.-C. and Rogers, M.B. (2008) Mycoplasma Infection Transforms Normal Lung Cells and Induces Bone Morphogenetic Protein 2 Expression by Post-Transcriptional Mechanisms. Journal of Cellular Biochemistry, 104, 580-594.

[116]   Zhang, S., Tsai, S. and Lo, S.-C. (2006) Alteration of Gene Expression Profiles during Mycoplasma-Induced Malignant Cell Transformation. BMC Cancer, 6, Article No. 116.

[117]   Zella, D., Curreli, S., Benedetti, F., Krishnan, S., Cocchi, F., Latinovic, O.S., Denaro, F., Romerio, F., et al. (2018) Mycoplasma Promotes Malignant Transformation in Vivo, and Its DnaK, a Bacterial Chaperone Protein, Has Broad Oncogenic Properties. Proceedings of the National Academy of Sciences of the United States of America, 115, E12005-E12014.

[118]   Matsuda, K. (2015) A Novel Therapeutic Strategy for Mycoplasma Infectious Disease. Personalized Medicine Universe, 4, 32-39.

[119]   Cameron, D.J., Johnson, L.B. and Maloney, E.L. (2014) Evidence Assessments and Guideline Recommendations in Lyme Disease: The Clinical Management of Known Tick Bites, Erythema Migrans Rashes and Persistent Disease. Expert Reviews of Anti-Infective Therapy, 12, 1103-1135.

[120]   Horowitz, R.I. and Freeman, P.R. (2019) Precision Medicine: Retrospective Chart Review and Data Analysis of 200 Patients on Dapsone Combination Therapy for Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome: Part 1. International Journal of General Medicine, 12, 101-119.

[121]   Horowitz, R.I. and Freeman, P.R. (2018) Precision Medicine: The Role of MSIDS Model in Defining, Diagnosing and Treating Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome and Other Chronic Illnesses: Part 2. Healthcare (Basel), 6, Article 129.

[122]   Nicolson, G.L., Nicolson, N.L. and Haier, J. (2007) Chronic Fatigue Syndrome Patients Subsequently Diagnosed with Lyme Disease Borrelia burgdorferi: Evidence for Mycoplasma Species Co-Infections. Journal of Chronic Fatigue Syndrome, 14, 5-17.

[123]   Nicolson, G.L. (2017) Mycoplasma and Other Intracellular Bacterial Infections in Rheumatic Diseases: Comorbid Condition or Cause? Open Journal of Tropical Medicine, 1, 016-017.

[124]   Biondi, E., McCulloh, R., Alverson, B., Klein, A., Dixon, A. and Ralston, S. (2014) Treatment of Mycoplasma pneumoniae: A Systematic Review. Pediatrics, 133, 1081-1090.

[125]   Kenny, G.E. and Cartwright, F.D. (2001) Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and Quinolones. Antimicrobial Agents and Chemotherapy, 45, 2604-2608.

[126]   Arai, S., Gohara, Y., Kuwano, K. and Kawashima, T. (1992) Antimycoplasmal Activities of New Quinolones, Tetracyclines and Macrolides against Mycoplasma pneumoniae. Antimicrobial Agents and Chemotherapy, 36, 1322-1324.

[127]   Hannan, P.C.T. (1998) Comparative Susceptibilities of Various AIDS-Associated and Human Genital Tract Mycoplasmas and Strains of Mycoplasma pneumoniae to 10 Classes of Antimicrobial Agents in Vitro. Journal of Medical Microbiology, 47, 1115-1122.

[128]   Renaudin, H. and Bébéar, C. (1990) Comparative in Vitro Activity of Azithromycin, Clarithromycin, Erythromycin and Lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. European Journal of Clinical Microbiology and Infectious Diseases, 9, 838-841.

[129]   Roberts, M.C., Koutsky, L.A., Holmes, K.K., LeBlanc, D.L. and Kenny, G.E. (1985) Tetracycline-Resistant Mycoplasma hominis Strains Contain Streptococcal tetM Sequences. Antimicrobial Agents and Chemotherapy, 28, 141-143.

[130]   Roberts, M.C. and Kenny, G.E. (1986) Dissemination of the tetM Tetracycline Resistance Determinant to Ureaplasma urealyticum. Antimicrobial Agents and Chemotherapy, 29, 350-352.

[131]   Bébéar, C.M., Renaudin, J., Charron, A., Renaudin, H., de Barbeyrac, B., Schaeverbeke, T. and Bébéar, C. (1999) Mutations in the gyrA, parC and parE Genes Associated with Fluoroquinolone Resistance in Clinical Isolates of Mycoplasma hominis. Antimicrobial Agents and Chemotherapy, 43, 954-956.

[132]   Nicolson, G.L. (1998) Some Considerations When Undergoing Treatment for Chronic Illnesses and Autoimmune Diseases, plus Supplemental Suggestions. International Journal of Medicine, 1, 123-128.

[133]   Nicolson, G.L., Nasralla, M.Y., Franco, A.R., Nicolson, N.L., Erwin, R., Ngwenya, R. and Berns, P.A. (2000) Diagnosis and Integrative Treatment of Intracellular Bacterial Infections in Chronic Fatigue and Fibromyalgia Syndromes, Gulf War Illness, Rheumatoid Arthritis and Other Chronic Illnesses. Clinical Practice of Alternative Medicine, 1, 92-102.

[134]   D’Alonzo, R., Mencaroni, E., Di Genova, L., Laino, D., Principi, N. and Esposito, S. (2018) Pathogenesis and Treatment of Neurological Diseases Associated with Mycoplasma pneumoniae Infection. Frontiers in Microbiology, 9, Article 2751.

[135]   Tilley, B.C., Alarcon, G.S., Heyse, S.P., Trentham, D.E., Neuner, R., Kaplan, D.A., Clegg, D.O., Leisen, J.C.C., Buckley, L., Cooper, S.M., Duncan, H., Pillemer, S.R., Tuttleman, M. and Fowler, S.E. (1995) Minocycline in Rheumatoid Arthritis: A 48-week, Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine, 122, 81-89.

[136]   Suzuki, S., Yamazaki, T., Narita, M., Okazaki, N., Suzuki, I., Andoh, T., Matsuoka, M., Kenri, T., Arakawa, Y. and Sasaki, T. (2006) Clinical Evaluation of Macrolide-Resistant Mycoplasma pneumoniae. Antimicrobial Agents and Chemotherapy, 50, 709-712.

[137]   Todd, S.R., Dahlgren, F.S., Traeger, M.S., Beltrán-Aguilar, E.D., Marianos, D.W., Hamilton, C., McQuiston, J.H. and Regan, J.J. (2015) No Visible Dental Staining in Children Treated with Doxycycline for Suspected Rocky Mountain Spotted Fever. Journal of Pediatrics, 166, 1246-1251.

[138]   Wang, M., Wang, Y., Yan, Y., Zhu, C., Huang, L., Shao, X., Xu, J., Zhu, H., Sun, X., Ji, W. and Chen, Z. (2014) Clinical and Laboratory Profiles of Refractory Mycoplasma pneumoniae Pneumonia in Children. International Journal of Infectious Diseases, 29, 18-23.

[139]   Bradshaw, C.R., Jensen, J.S. and Waites, K.B. (2017) New Horizons in Mycoplasma genitalium Treatment. Journal of Infectious Diseases, 216, S412-S419.

[140]   Chopra, I. and Roberts, M. (2001) Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology and Epidemiology of Bacterial Resistance. Microbiology and Molecular Biology Reviews, 65, 232-260.

[141]   Butler, T. (2017) The Jarish-Herxheimer Reaction after Antibiotic Treatment of Spirochetal Infections: A Review of Recent Cases and Our Understanding of Pathogenesis. The American Journal of Tropical Medicine and Hygiene, 96, 46-52.

[142]   Wormser, G.P., Dattwyler, R.J., Shapiro, E.D., Halperin, J.J., Steere, A.C., Klempner, M.S., Krause, P.J., Bakken, J.S., Strie, F., Stanek, G., Bockenstedt, L., Fish, D., Dumler, J.S. and Nadelman, R.B. (2006) The Clinical Assessment, Treatment and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis and Babesiosis: Clinical Practice Guidelines by the Infectious Disease Society of America. Clinical Infectious Diseases, 43, 1089-1134.

[143]   Lebeaux, D., Ghigo, J.-M. and Belion, C. (2014) Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics. Microbiology and Molecular Biology Reviews, 78, 510-543.

[144]   Lewis, K. (2006) Persister Cells, Dormancy and Infectious Disease. Nature Reviews Microbiology, 5, 48-56.

[145]   Fox, R.I. (1993) Mechanism of Action of Hydroxychloroquine as an Antirheumatic Drug. Seminars in Arthritis and Rheumatism, 32, 82-91.

[146]   Lee, K.-Y., Lee, H.-S., Jong, J.-H., Lee, M.-H., Lee, J-S., Burgner, D. and Lee, B.-C. (2006) Role of Prednisolone Treatment in Severe Mycoplasma pneumoniae Pneumonia in Children. Pediatric Pulmonology, 41, 263-268.

[147]   Hughes, R.A., Swan, A.V. and van Doorn, P.A. (2014) Intravenous Immunoglobulins for Guillain-Barré Syndrome. Cochrane Database of Systematic Reviews, 2014, Article CD002063.

[148]   Chevert, S., Hughes, R.A. and Annane, D. (2017) Plasma Exchange for Guillain-Barré Syndrome. Cochrane Database of Systematic Reviews, 2017, Article CD001798.

[149]   Yrjänheikki, J., Tikka, T., Keinänen, R., Goldsteins, G., Chan, P.H. and Koistinaho, J. (1999) A Tetracycline Derivative, Minocycline, Reduces Inflammation and Protects against Focal Cerebral Ischemia with a Wide Therapeutic Window. Proceedings of the National Academy of Sciences of the United States of America, 96, 13496-13500.

[150]   Tamaoki, J., Kadota, J. and Takizawa, H. (2004) Clinical Implications of the Immunomodulatory Effects of Macrolides. The American Journal of Medicine Supplements, 117, 5-11.

[151]   Horowitz, R.I. (2017) How Can I Get Better? An Action Plan for Treating Resistant Lyme and Chronic Disease. St. Martin’s Press, New York.

[152]   Nicolson, G.L. and Ngwenya, R. (2001) Dietary Considerations for Patients with Chronic Illnesses and Multiple Chronic Infections. A Brief Outline of Eighteen Dietary Steps to Better Health. Townsend Letter, 219, 63-65.

[153]   Buhner, S.H. (2013) Healing Lyme Disease Coinfections. Complementary and Holistic Treatments for Bartonella and Mycoplasma. Healing Arts Press, Rochester.

[154]   Anderson, C.J. (2015) Bioactive Eggs Components and Inflammation. Nutrients, 7, 7889-7913.

[155]   Nicolson, G.L. (2014) Mitochondrial Dysfunction and Chronic Disease: Treatment with Natural Supplements. Alternative Therapies in Health and Medicine, 20, 18-25.

[156]   Nicolson, G.L. (2014) Mitochondrial Dysfunction and Chronic Disease: Treatment with Natural Supplements. Integrative Medicine, 13, 35-43.

[157]   Dunstan, R.H., Sparkes, D.L., Roberts, T.K., Crompton, M.J., Gottfries, J. and Dascombe, B.J. (2013) Development of a Complex Amino Acid Supplement, Fatigue RevivaTM, or Oral Ingestion: Initial Evaluations of a Product Concept and Impact on Symptoms of Sub-Health in a Group of Males. Nutrition Journal, 12, Article No. 115.

[158]   Schmidt, H.H.W., Stocker, R., Vollbracht, C., Paulsen, G., Riley, D., Daiber, A. and Cuadrado, A. (2015) Antioxidants in Translational Medicine. Antioxidants and Redox Signaling, 23, 1130-1143.

[159]   Burri, B.J., La Frano, M.R. and Zhu, C. (2016) Absorption, Metabolism and Functions of Beta-Cryptoxanthin. Nutrition Reviews, 74, 69-82.

[160]   Nicolson, G.L., Ferreira de Mattos, G., Settineri, R., Costa, C., Ellithorpe, R., Rosenblatt, S., La Valle, J., Jimenez, A. and Ohta, S. (2016) Clinical Effects of Hydrogen Administration: From Animal and Human Diseases to Exercise Medicine. International Journal of Clinical Medicine, 7, 32-76.

[161]   Ohsawa, I., Ishikawa, M., Takahashi, K., Watanabe, M., Nishimaki, K., Yamagata, K., Katsura, K., Katayama, Y., Asoh, S. and Ohta, S. (2007) Hydrogen Acts as a Therapeutic Antioxidant by Selectively Reducing Cytotoxic Oxygen Radicals. Nature Medicine, 13, 688-694.

[162]   Kaufmann, G.F. and Schlievert, P.M. (2015) Non-Aqueous Glycerol Monolaurte Get Exhibits Antibacterial and Anti-Biofilm Activity against Gram-Positive and Gram-Negative Pathogens. PLoS ONE, 10, e120280.

[163]   Theophilus, P.A.S., Victoria, M.J., Socarras, K.M., Filush, K.R., Gupta, K., Luecke, D.F. and Sapi, E. (2015) Effectiveness of Stevia rebaudiana Whole Leaf Extract against the Various Morphological Forms of Borrelia burgforferi in Vitro. European Journal of Microbiology and Immunology, 5, 268-280.

[164]   Mirtaheri, E., Gargari, B.P., Kolahi, S., Dehghan, P., Asghari-Jafarabadi, M., Hajalilou, M., Novin, Z.S. and Abbasi, M.M. (2015) Effects of Alpha-Lipoic Acid Supplementation on Inflammatory Biomarkers and Matrix Metalloproteinase-3 in Rheumatoid Arthritis Patients. Journal of the American College of Nutrition, 34, 310-317.

[165]   Gareau, M.G., Sherman, P.M. and Walker, W.A. (2010) Probiotics and the Gut Microbiota in Intestinal Health and Disease. Nature Reviews of Gastroenterology and Hepatology, 7, 503-514.

[166]   Rondanelli, M., Faliva, M.A., Perna, S., Giacosa, A., Peroni, G. and Castellazzi, A.M. (2017) Using Probiotics in Clinical Practice: Where Are We Now? A Review of Existing Meta-Analyses. Gut Microbes, 8, 521-543.

[167]   Surawicz, C.M. (2008) Role of Probiotics in Antibiotic-Associated Diarrhea, Clostridium difficile-Associated Diarrhea, and Recurrent Clostridium difficile-Associated Diarrhea. Journal of Clinical Gastroenterology, 42, S64-S70.

[168]   Franzoso, G., Hu, P.C., Meloni, G.A. and Barile, M.F. (1994) Immunoblot Analyses of Chimpanzee Sera after Infection and after Immunization and Challenge with Mycoplasma pneumoniae. Infection and Immunity, 62, 1008-1014.

[169]   Smith, C.B., Friedewald, W.T. and Chanock, R.M. (1967) Inactivated Mycoplasma pneumoniae Vaccine. Evaluation in Volunteers. JAMA, 199, 353-358.

[170]   Brown, R.C., Hendley, J.O. and Gwaltney Jr., J.M. (1972) Mycoplasma pneumonaie Vaccine: Antigenicity or Fubbered Antigens in Volunteers. Infection and Immunity, 5, 657-661.

[171]   Nicolson, G.L., Rosenblatt, S., Ferreira de Mattos, G., Settineri, R., Breeding, P.C., Ellithorpe, R.R. and Ash, M.E. (2016) Clinical Uses of Membrane Lipid Replacement Supplements in Restoring Membrane Function and Reducing Fatigue in Chronic Diseases and Cancer. Discoveries, 4, e54. Nicolson.pdf

[172]   Nicolson, G.L. and Ash, M.E. (2017) Membrane Lipid Replacement for Chronic Illnesses, Aging and Cancer Using Oral Glycerolphospholipid Formulations with Fructooligosaccharides to Restore Phospholipid Function in Cellular Membranes, Organelles, Cells and Tissues. Biochimica et Biophysica Acta, 1859, 1704-1724.

[173]   Nicolson, G.L. (2016) Membrane Lipid Replacement: Clinical Studies Using a Natural Medicine Approach to Restoring Membrane Function and Improving Health. International Journal of Clinical Medicine, 7, 133-143.

[174]   Nicolson, G.L., Settineri, R., Ferreira, G. and Breeding, P. (2018) Reduction of Pain, Fatigue, Gastrointestinal and Other Symptoms and Improvement in Quality of Life Indicators in Fibromyalgia Patients with Membrane Lipid Replacement Glycerolphospholipids and Controlled-Release Caffeine. International Journal of Clinical Medicine, 9, 560-579.